Paratek is developing novel antibiotics based upon its expertise in tetracycline chemistry. The company was formed from a reverse merger with Nasdaq-listed Transcept Pharmaceuticals and Abingworth Partner, Michael Bigham, joined the combined company as Chairman and CEO. Paratek is a VIPE (Venture Investment in Private Equity). The company's lead product, a new broad-spectrum antibiotic, has been approved in the US for community-acquired bacterial pneumonia and for acute skin and skin structure infections.

LocationBoston, MA
CEOEvan Loh